Title Cancer Pharmacology
Subtitle An Illustrated Manual of Anticancer Drugs
Author Ashkan Emadi, Judith E. Karp
ISBN 9780826162038
List price USD 99.00
Price outside India Available on Request
Original price
Binding Paperback
No of pages 312
Book size 178 x 254 mm
Publishing year 2020
Original publisher Demos Medical Publishing
Published in India by .
Exclusive distributors .
Sales territory Bangladesh, India, Pakistan, Sri Lanka
Status New Arrival
About the book Send Enquiry
  
 

Description:

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs provides a one-stop guide to the essential basic and clinical science of all the effective, life-prolonging drug therapies in oncology. From traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon malignancies. Beautifully illustrated throughout, each chapter contains visually engaging figures detailing the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic, and molecular properties of the various agents, and their mechanisms of action. As the first illustrated book of its kind, this highly visual text uses a uniform approach to each cancer drug class and agent presented in the book, and covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Flow diagrams, clinical tables, and bulleted text further explain important information pertaining to each cancer drug class including their indications, mechanisms of action, potential adverse reactions, dosing and dose adjustments, and safety monitoring. Organized in an easy-to-digest format and replete with detailed images, clinical pearls, and end of chapter Q&As, this evidence-based reference presents all major classes, agents, targets, and approaches to cancer pharmacotherapy.

Whether you are a trainee, a clinical scientist, or a clinician in practice, the book is an ideal reference. It presents challenging information in an instructional way, illustrates key concepts for ease of retention, and poses tough questions so readers can problem solve potential scenarios and test their pharmacologic acumen. Written by leading experts in oncopharmacology, this first-of-its kind manual is a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology including clinicians, pharmacists, nurses, and trainees.


KEY FEATURES:

  • In includes visual depictions of chemical structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents
  • Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other modalities
  • Over 100 highly stylized images and numerous comprehensive tables
  • Covers challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments
  • All chapters conclude with clinical pearls and detailed clinical Q&As with descriptive rationales


Contents:

Contributors

Preface

Chapter 1. Anticancer Drug Development: An Introduction (Edward A. Sausville) • Introduction • Pathophysiology of Cancer, Where Cancer Drugs Come From • How Do We Know a Cancer Drug Might Be Useful? • Why Do Cancer Drugs Work at All, Stop Working, or Never Work? • Pharmacokinetics: Action of the Host on an Administered Drug • Limitations to Effective Drug Action • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 2. Alkylating Agents (Ali Bukhari and Ashkan Emadi) • Introduction • Nitrogen Mustards • Nitrosoureas • Triazines • Ethylenimines • Platinum Compounds • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 3. Antimetabolites: Hydroxyurea, Pyrimidine and Purine Analogs, and L-Asparaginase (Crystal Lu, Judith E. Karp, and Ashkan Emadi) • Introduction • Ribonucleotide Reductase Inhibition • Pyrimidine Analog • Purine Analogs • Asparaginase • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 4. Antimetabolites: Antifolates (Justin Lawson and Edward A. Sausville) • Introduction • Role of Folic Acid in Metabolism • Antifolates and Their Mechanism of Action • Folate Transporters • Intracellular Metabolism of Folate and Antifolates • Absorption and Elimination of Antifolates • Antifolate Adverse Events • Toxicity and Rescue With High-Dose Methotrexate Regimens • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 5. Antimitotics (Edward A. Sausville) • Introduction • Vinca Alkaloids • Taxanes • Newer Microtubule-Directed Agents • Ixabepilone • Eribulin • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 6. DNA Repair, Apoptotic Pathways, CDK Inhibitors (Mira A. Kohorst and Scott H. Kaufmann) • Introduction • Topoisomerases: Endogenous Enzymes That Become Agents of DNA Damage • Targeting the DNA Damage Response • Targeting the ATR–CHK1–WEE1 Pathway to Inhibit the Replication Checkpoint • Targeting DNA-PK • PARP Inhibitors • Activating Apoptosis: BH3 Mimetics and Beyond • CDK Inhibitors: Targeting the Cell Cycle, Antiapoptotic Proteins, and More • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 7. Epigenetic Modulators (Lukasz P. Gondek) • Introduction • Chromatin Structure and Epigenetic Marks • Epigenetics Modifying Agents and the Mechanism of Action • Bromodomain Inhibitors • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 8. Differentiating Agents and Microenvironment (Gabriel Ghiaur) • Introduction • Tumor Stem Cells and Their Microenvironment • Effects of the Tumor Microenvironment on Pharmacokinetics • Effects of the Tumor Microenvironment on Pharmacodynamics • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 9. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer (Amy Fulton and Katherine H. R. Tkaczuk)Introduction • Dedication • Estrogen Receptor in Breast Cancer • Selective Estrogen Receptor Modulators • Aromatase Inhibitors • AIs in Combination With Kinase Inhibitors • Selective Estrogen Receptor Degraders • Ovarian Suppression • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 10. Male Hormonal Therapies (Vincent C. O. Njar and Arif Hussain) • Introduction • Prostate Cancer and Androgens Biosynthesis • Androgen Receptor Biology and Signaling in Prostate Cancer • Therapeutic Strategies for Prostate Cancer • Androgen Deprivation Therapy • GnRH Agonists and Antagonists • Inhibitors of 17a-Hydroxylase/17, 20-Lyase (CYP17) • AR Antagonists (Antiandrogens) • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 11. Targeted Therapies (Small Molecules) (Michael G. McCusker, Jr., Katherine A. Scilla, and Christian Rolfo) • Introduction • Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor • Vascular Endothelial Growth Factor (VEGF) Receptor • Mitogen-Activated Protein Kinase Pathway • Anaplastic Lymphoma Kinase • B-Cell Receptor-ABL • Isocitrate Dehydrogenase and Ten-Eleven Translocation • Bruton Tyrosine Kinase • Janus Kinase/Signal Transducer and Activator of Transcription • FMS-Like Tyrosine Kinase 3 • Type I and Type II Tyrosine Kinase Inhibitors • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 12. Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents (Alison Duffy and Ciera Patzke) • Introduction • Naked Monoclonal Antibodies • Antibody–Drug Conjugates • Radioimmunoconjugates • Cytokine Therapy • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 13. Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors (Mark Yarchoan and Elizabeth Jaffee) • Introduction • Tumors Orchestrate a Complex Signaling Network to Evade • Immune Destruction • When Functioning Normally, CD8+ T Effector Cells Can Recognize and Destroy Tumor Cells Through the Identification of Aberrant Proteins (Neoantigens) That Are Presented on the Surface of Tumors • Anti-PD-1 and Anti-PD-L1 Immunotherapies Have Demonstrated Unprecedented Clinical Activity in a Wide Range of Different Cancer Types, While Other Cancers Have Not Responded to These Agents • The First Approved Immune Checkpoint Inhibitors Restore Anti-Tumor Immunity by Blocking the PD-1/PD-L1 Axis, or by Blocking the Inhibitory Molecule CTLA-4 • Immune Checkpoint Inhibitors Can Cause a Wide Range of Immune-Related Adverse Effects (irAEs), Which Can Be Serious and Limit the Use of Immune Checkpoint Inhibitors in Patients With Cancer • Prophylactic Vaccines Stimulate the Immune System Against a Disease Not Yet Experienced by the Host • Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies Are Two Novel Therapeutic Approaches to Cancer Immunotherapy • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 14. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention (Mehmet Kocoglu) • Introduction • Alkylating Agents • Immunomodulatory Drugs (IMiDs) • Proteasome Inhibitors • Corticosteroids • Antibodies • Other Immune Therapies • Epigenetic Modulators • Other ANTI-MM Drugs • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 15. Transplant-Related Agents (Jean Yared and Saurabh Dahiya) • Introduction • Drugs Used in Transplant Conditioning Regimens • Drugs Used for Prevention and Treatment of GVHD • Calcineurin-Dependent Mechanisms • Calcineurin-Independent Mechanisms • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 16. Basic Drug Development With Structural Considerations (Sonia Esparza and Joshua Zeidner) • Introduction • Phases of Clinical Trials • Clinical Trial Facts • Patient Selection and Study Design • New Active Substance Launches From 2011 to 2016 by Indication • Novel Therapeutic Strategies in Oncology • Survival Endpoints • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 17. Integral Components in Development of Clinical Trials: PK/PD, Statistics, and Principles of Rational Combinatorial Therapies (S. Percy Ivy and Richard F. Little) • Introduction • Clinical Trials Life Cycle • Clinical Drug Development Triad • Basic and Translation Approach to Clinical Trials • Pharmacodynamic and Descriptive/Biological Biomarkers • Characterization and Selection of Biomarkers • Development of Biomarkers Based on Their Intended Use • Prognostic Biomarkers • Predictive Biomarker • Targeted Cancer Therapies • Early-Phase Clinical Trials Using Adaptive Designs • Early-Phase Clinical Trials Using Adaptive Designs • Pathways to Drug Development • The Flow of Biomarker Identification, Validation, and Application • The Pharmacological Audit Trial (PhAT) • Comparison of the Molecular Pharmacological Audit Trial (MoPhAT) to the Pharmacological Audit Trial (PhAT) • Biomarkers in Clinical Trials • Chapter Summary • Clinical Pearls • Multiple Choice Questions • Answers to Multiple Choice Questions

Chapter 18. Drug Approval and Regulatory Issues (Olanrewaju O. Okusanya, Ruby Leong, Matthew D. Thompson, and Donna Przepiorka) • Introduction • IND—Enabling Nonclinical Studies for Cancer Drugs • Getting to the Recommended Phase 2 dose (RP2D) • Studies Contributing to Dose Refinement • Additional Pharmacology Considerations for Cancer Drug Marketing Applications • Chapter Summary • Multiple Choice Questions • Answers to Multiple Choice Questions

Index


About the Editors:

Ashkan Emadi, MD, PhD

Professor, Medicine and Pharmacology

Associate Director for Clinical Research

Marlene and Stewart Greenebaum Comprehensive Cancer Center

Director, Translational Genomics Laboratory, University of Maryland School of Medicine, Baltimore, Maryland

 

Judith E. Karp, MD

Professor Emerita, Oncology and Medicine

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland


Target Audience:

A “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology including clinicians, pharmacists, nurses, and trainees.

 
Special prices are applicable to the authorised sales territory only.
Prices are subject to change without prior notice.